Category: Herbs & Ingredients
Saffron is the world's most expensive spice and, unexpectedly, one of the more-studied botanicals for low mood. Here is what the meta-analyses actually show, the 30mg standardised dose the trials use, where the evidence is thin, and the safety points that matter.
Category: Herbs and Ingredients | Reading time: ~12 min | Level: Introductory
Saffron is best known as the most expensive spice on earth, the deep-red threads that turn a paella gold and cost more by weight than silver. What far fewer people know is that this kitchen luxury has quietly accumulated one of the more surprising research files in the botanical world, not for digestion or immunity, but for mood. It is an unlikely candidate, and that unlikeliness is part of why the evidence is worth reading carefully rather than dismissing or overselling.
So this piece asks a straightforward question. When researchers have actually tested saffron for low mood, what have they found, how good are those studies, and what would using it sensibly look like? The short version is that saffron has a genuinely more encouraging evidence base than most herbs marketed for mood, that the honest grade is still limited to moderate rather than strong, and that a specific standardised dose, around 30mg a day, is what the research settled on. As with anything touching mood, the caveats matter as much as the findings.
This is an educational read about mood and low mood, not a claim that saffron treats, prevents or cures depression or any other condition. Persistent or worsening low mood deserves a proper clinical assessment, and nothing here is a substitute for that.
Saffron is harvested from Crocus sativus, the saffron crocus, and specifically from the three delicate red stigmas at the centre of each flower. Those threads have to be picked by hand, which is why saffron is so costly, and they have been used as a spice, a dye and a folk remedy across Persia, the Mediterranean and South Asia for thousands of years. The mood-related interest is not purely modern; traditional texts describe saffron as gladdening or uplifting, which is part of what prompted researchers to test it.
Its biological activity is attributed to a handful of compounds, chiefly the carotenoid pigments crocin and crocetin, which give saffron its colour, and safranal, which carries much of its aroma. In laboratory and animal work these compounds interact with brain signalling systems involved in mood, including serotonin pathways, which offers a plausible mechanism for the clinical findings. Plausible mechanism plus positive trials is a stronger position than either alone, though it is still not proof of a large effect.
The one framing sentence to keep: saffron is a spice whose pigment and aroma compounds show mood-related activity in the laboratory, and, unusually for a culinary botanical, that activity has been tested in a fair number of human mood trials.
The saffron mood literature is larger than you would expect and consistently pointed in one direction, which is what makes it interesting, and it is smaller and narrower than the enthusiasts imply, which is what keeps the grade honest.
A frequently cited meta-analysis by Hausenblas and colleagues, published in the Journal of Integrative Medicine in 2013, pooled randomised trials of saffron for major depressive symptoms and concluded that saffron performed better than placebo, with several head-to-head trials finding its effect comparable to standard antidepressants such as fluoxetine and imipramine [1]. A systematic review by Lopresti and Drummond reached similar conclusions and examined the plausible antidepressant mechanisms behind them [2]. A later and broader systematic review and meta-analysis by Marx and colleagues in Nutrition Reviews extended the picture to both depressive and anxiety symptoms, again reporting benefit over placebo [3]. Beyond clinical depression, standardised-extract trials have tested saffron in people with low mood who do not have a diagnosis, with some positive results at around the 30mg dose [4].
That is a genuinely more substantial and more consistent body of evidence than most mood botanicals can show. Now the honest brakes. Many of the trials are small, often a few dozen participants each. Most are short, commonly six to eight weeks. A large share of the research has come from a narrow set of research groups in one region where saffron is cultivated, which raises the standard concerns about independent replication and publication bias that apply whenever a field's evidence is geographically and commercially concentrated. And "comparable to an antidepressant in a small trial" is an encouraging signal, not a demonstration of equivalence, because small studies are exactly where apparent equivalence is least reliable.
Weighing all of that, the fair grade is limited to moderate. The direction of effect is consistently positive across a reasonable number of trials, which is more than can be said for many herbs. The certainty is held back by small samples, short durations, and concentration of the research, which is why it is not yet strong. That is a genuinely respectable position for a botanical, stated without inflation.
If low mood is what brought you here, saffron is one of the more defensible botanical options to consider, provided you keep it in proportion and in its lane.
Use the studied form and dose. The trials used standardised extracts, made to defined levels of active compounds, at around 30mg per day, often split into two 15mg doses. This is not the same as cooking with saffron, and culinary saffron, used in pinches and frequently adulterated in the marketplace, is not a substitute for the studied intervention. If you try saffron for mood, a standardised extract at that dose is what the evidence points to.
Give it a fair trial. The benefit in the studies built over several weeks. A few days is not a test. Six to eight weeks is closer to a reasonable window, and if there is no meaningful change in that time, it is fair to conclude it is not helping you.
Keep the foundations in place. Saffron, at best, sits alongside the things with the deepest evidence for mood: sleep, physical activity, social connection and, where needed, professional care. It is a possible adjunct, not a replacement for any of those.
Know when to escalate. Low mood that is persistent, worsening, or accompanied by loss of function or thoughts of self-harm is a reason to see a clinician promptly, not to keep experimenting with supplements. Saffron is for the mild, exploratory end of the spectrum, and even there, professional input is wise if things do not improve.
What to ask a clinician: whether saffron is sensible given your history and any medication, particularly if you take an antidepressant, and whether your low mood warrants a fuller assessment.
At the studied dose, saffron is generally well tolerated, but several cautions genuinely matter and belong under their own heading.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
Saffron is the kind of ingredient PlantRx enjoys covering, because the honest story is genuinely interesting and does not need embellishment. Here is a culinary luxury with a plausible mechanism and a more consistent mood-trial record than most of the herbs sold for the same purpose, and the fair grade is a respectable limited-to-moderate rather than the "clinically proven" language a store wearing a lab coat would reach for. Telling you exactly that, including the specific 30mg dose the research settled on and the reasons the evidence is not yet strong, is worth more than another round of overclaiming.
If you explore saffron, do it in the studied form, give it weeks not days, keep the foundations of mood in place, and treat persistent low mood as a reason to see someone, not to keep trying supplements. When we grade an ingredient in the Remedy Library, this is the balance we aim for: neither dismissing a real signal nor inflating it past what the trials support. Saffron happens to land on the more promising side of that line, which is a pleasant thing to be able to say honestly.
For the connected reads, see the honest guide to serotonin and mood, the piece on ashwagandha for stress, and the wider look at what actually helps low mood.
1. Hausenblas HA, et al. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. Journal of Integrative Medicine. 2013. Meta-analysis; saffron superior to placebo, comparable to antidepressants in small head-to-head trials. 2. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms. Human Psychopharmacology. 2014. Systematic review. Verify exact citation before publish. 3. Marx W, et al. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutrition Reviews. 2019. Systematic review and meta-analysis. Verify exact citation before publish. 4. Kell G, et al. / Lopresti AL, et al. A standardised saffron extract (affron) for low mood: randomised controlled trial at approximately 28 to 30mg. Complementary Therapies in Medicine. 2017. Verify exact citation before publish. 5. National Center for Complementary and Integrative Health; European Medicines Agency assessment. Saffron safety, dosing and pregnancy cautions. 2020. Government and regulatory review. Verify specific statements before publish.
The evidence is more encouraging than for most botanicals, but it should be read honestly. Several small randomised trials and meta-analyses report that a standardised saffron extract improved low-mood symptoms more than placebo, and some head-to-head studies found effects comparable to standard antidepressants. The honest grade is limited to moderate, because the trials are mostly small, short and geographically concentrated. Saffron is not a treatment for diagnosed depression, and anyone with a mood disorder should work with a clinician rather than self-treat.
The trials converged on roughly 30mg per day of a standardised extract, frequently split into two 15mg doses, taken over several weeks. This is a specific extract dose, not the pinch of culinary saffron you cook with, and the standardised products used in studies are made to defined levels of the active compounds. There is no basis for assuming a cooking-grade amount matches the trial dose.
In the studies that reported benefit, the effect built over several weeks rather than appearing immediately, with typical trial lengths of six to eight weeks. As with most mood-related interventions, a fair trial period is weeks, not days, and a few doses is not a meaningful test.
At the roughly 30mg extract dose used in studies, saffron is generally well tolerated, with occasional mild effects like changes in appetite or a headache. The important cautions are that much higher amounts are genuinely toxic, that it must be avoided in pregnancy, and that combining it with prescription antidepressants should only be done with medical guidance. If you are pregnant, breastfeeding, or on medication, check with a healthcare professional first.
Not without a clinician's input. Because saffron is being studied for the same mood pathways that many antidepressants act on, combining them raises theoretical concerns about additive effects, and it is not something to self-manage. Speak to the prescriber who manages your medication before adding saffron, and do not stop a prescribed antidepressant to try it.
Not for these purposes. The trials used standardised extracts made to defined levels of active compounds and dosed precisely at around 30mg. Culinary saffron varies widely in quality and potency, is used in tiny amounts, and is often adulterated in the marketplace. Cooking with saffron is a pleasure, but it is not the same as the studied intervention.
It is one of the better-evidenced botanical options for low mood, but keep it in proportion. The studies are small and short, the grade is limited to moderate, and low mood that is persistent or worsening deserves a proper assessment rather than self-treatment. If you try a standardised 30mg extract, give it several weeks, keep the basics of sleep, movement and connection in place, and see a clinician if things do not lift.
Read that carefully. Some small head-to-head trials found comparable effects, but small studies from a narrow set of research groups are not the same as large independent proof, and matching a drug in a small trial is not a licence to treat saffron as a replacement for prescribed treatment. It is an encouraging signal that warrants better studies, not a settled equivalence.
Saffron is cultivated heavily in Iran, and much of the clinical research has come from Iranian groups, which is a natural consequence of local interest and access. It is not a criticism of the studies themselves, but geographic and research-group concentration is one reason independent replication elsewhere matters before the evidence can be called strong.